- Phase 1 studies published in March 22, 2012 issue of New England Journal of Medicine
- Phase 2 studies to be presented March 25-26 at American College of Cardiology Annual Meeting
TARRYTOWN, NY, USA I March 21, 2012 I Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN – News) today announced that results of the Phase 1 clinical program with their investigational product REGN727/SAR236553, a novel, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9 serine protease) were published in the March 22, 2012 issue of the New England Journal of Medicine. The primary author of the article, entitled "Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol," was Evan A. Stein, M.D., Ph.D., Director of the Metabolic and Atherosclerosis Research Center in Cincinnati, Ohio, and Principal Investigator of one of the REGN727/SAR236553 Phase 1 clinical trials.
Additionally, results of two of three completed Phase 2 studies of REGN727/SAR236553 will be presented at oral sessions at the American College of Cardiology (ACC) annual meeting. The presentations are:
"A Randomized, Double-Blind, Placebo-Controlled Trial Of The Safety And Efficacy of a Monoclonal Antibody To Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, REGN727/SAR236553, in Patients With Primary Hypercholesterolemia" will be presented by James M. McKenney, Pharm.D, Professor Emeritus, Virginia Commonwealth University School of Medicine, during a Late-Breaking Clinical Trial session on Monday, March 26 at 11:14 AM.
"The Effects of Co-administering a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, REGN727/SAR236553, with 10 and 80 mg Atorvastatin Compared to 80 mg Atorvastatin Alone in Patients With Primary Hypercholesterolemia" will be presented by Eli M. Roth, M.D., Professor of Clinical Medicine and Director of Preventive Cardiology for the Division of Cardiology, University of Cincinnati College of Medicine, on Sunday, March 25 at 8:25 AM.
About PCSK9
PCSK9 is known to be a determinant of circulating LDL levels, as it binds to LDL receptors resulting in their degradation so that fewer are available on liver cells to remove excess LDL-cholesterol from the blood. Moreover, traditional LDL-lowering therapies such as statins actually stimulate the production of PCSK9, which may limit their ability to lower LDL-cholesterol. Blocking the PCSK9 pathway is therefore a potentially novel mechanism for lowering LDL-cholesterol.
About REGN727
REGN727/SAR236553 is a fully-human monoclonal antibody directed against PCSK9, administered via subcutaneous injection. By inhibiting PCSK9, a determinant of circulating LDL-cholesterol levels in the blood, REGN727 increases the number of free LDL receptors which can bind to circulating LDL and clear it from the bloodstream. REGN727 was created using Regeneron’s pioneering VelocImmune® technology and is being developed by Regeneron in collaboration with Sanofi.
About Regeneron Pharmaceuticals
Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets two products in the United States, one for the treatment of neovascular (wet) age-related macular degeneration and another for the treatment of a rare inflammatory condition. Additionally, Regeneron has three regulatory applications pending before the U.S. Food and Drug Administration (FDA) and 10 drug candidates in clinical development. More information and recent news releases are available on the Regeneron web site at www.regeneron.com
SOURCE: Regeneron Pharmaceuticals
Post Views: 52
- Phase 1 studies published in March 22, 2012 issue of New England Journal of Medicine
- Phase 2 studies to be presented March 25-26 at American College of Cardiology Annual Meeting
TARRYTOWN, NY, USA I March 21, 2012 I Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN – News) today announced that results of the Phase 1 clinical program with their investigational product REGN727/SAR236553, a novel, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9 serine protease) were published in the March 22, 2012 issue of the New England Journal of Medicine. The primary author of the article, entitled "Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol," was Evan A. Stein, M.D., Ph.D., Director of the Metabolic and Atherosclerosis Research Center in Cincinnati, Ohio, and Principal Investigator of one of the REGN727/SAR236553 Phase 1 clinical trials.
Additionally, results of two of three completed Phase 2 studies of REGN727/SAR236553 will be presented at oral sessions at the American College of Cardiology (ACC) annual meeting. The presentations are:
"A Randomized, Double-Blind, Placebo-Controlled Trial Of The Safety And Efficacy of a Monoclonal Antibody To Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, REGN727/SAR236553, in Patients With Primary Hypercholesterolemia" will be presented by James M. McKenney, Pharm.D, Professor Emeritus, Virginia Commonwealth University School of Medicine, during a Late-Breaking Clinical Trial session on Monday, March 26 at 11:14 AM.
"The Effects of Co-administering a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, REGN727/SAR236553, with 10 and 80 mg Atorvastatin Compared to 80 mg Atorvastatin Alone in Patients With Primary Hypercholesterolemia" will be presented by Eli M. Roth, M.D., Professor of Clinical Medicine and Director of Preventive Cardiology for the Division of Cardiology, University of Cincinnati College of Medicine, on Sunday, March 25 at 8:25 AM.
About PCSK9
PCSK9 is known to be a determinant of circulating LDL levels, as it binds to LDL receptors resulting in their degradation so that fewer are available on liver cells to remove excess LDL-cholesterol from the blood. Moreover, traditional LDL-lowering therapies such as statins actually stimulate the production of PCSK9, which may limit their ability to lower LDL-cholesterol. Blocking the PCSK9 pathway is therefore a potentially novel mechanism for lowering LDL-cholesterol.
About REGN727
REGN727/SAR236553 is a fully-human monoclonal antibody directed against PCSK9, administered via subcutaneous injection. By inhibiting PCSK9, a determinant of circulating LDL-cholesterol levels in the blood, REGN727 increases the number of free LDL receptors which can bind to circulating LDL and clear it from the bloodstream. REGN727 was created using Regeneron’s pioneering VelocImmune® technology and is being developed by Regeneron in collaboration with Sanofi.
About Regeneron Pharmaceuticals
Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets two products in the United States, one for the treatment of neovascular (wet) age-related macular degeneration and another for the treatment of a rare inflammatory condition. Additionally, Regeneron has three regulatory applications pending before the U.S. Food and Drug Administration (FDA) and 10 drug candidates in clinical development. More information and recent news releases are available on the Regeneron web site at www.regeneron.com
SOURCE: Regeneron Pharmaceuticals
Post Views: 52
